Identification and Optimization of Anthranilic Sulfonamides as Novel, Selective Cholecystokinin-2 Receptor Antagonists
作者:Brett D. Allison、Victor K. Phuong、Laura C. McAtee、Mark Rosen、Magda Morton、Clodagh Prendergast、Terry Barrett、Guy Lagaud、Jamie Freedman、Lina Li、Xiaodong Wu、Hariharan Venkatesan、Marna Pippel、Craig Woods、Michèle C. Rizzolio、Michael Hack、Kenway Hoey、Xiaohu Deng、Christopher King、Nigel P. Shankley、Michael H. Rabinowitz
DOI:10.1021/jm060590x
日期:2006.10.1
A high throughput screening approach to the identification of selective cholecystokinin-2 receptor (CCK-2R) ligands resulted in the discovery of a novel series of antagonists, represented by 1-[2-[(2,1,3-benzothiadiazol-4-ylsulfonyl)amino]-5-chlorobenzoyl]-piperidine (1; CCK-2R, pK(I) = 6.4). Preliminary exploration of the structure-activity relationships around the anthranilic ring and the amide and
一种高通量筛选方法,用于鉴定选择性胆囊收缩素2受体(CCK-2R)配体,从而发现了一系列新型的拮抗剂,以1- [2-[(2,1,3-benzothiadiazol-4- (磺酰基)氨基] -5-氯苯甲酰基]-哌啶(1; CCK-2R,pK(I)= 6.4)。对邻氨基苯甲酸环以及酰胺和磺酰胺基团周围的结构活性关系的初步探索导致受体亲和力提高了近50倍,并且相对于相关的胆囊收缩素1受体显示出超过1000倍的选择性。药代动力学评估导致鉴定了4- [4-碘-2-[(5-喹喔啉基磺酰基)氨基]苯甲酰基]-吗啉,26d,